Why the study?
Does enoximone increase the probability of arrhythmias in pithed rats and isolated rabbit atria?
Does enoximone increase the probability of arrhythmias in pithed rats and isolated rabbit atria?
Preclinical evidence suggests that the phosphodiesterase inhibitor enoximone does not possess electrophysiologic properties that would increase the risk of arrhythmias at clinical concentrations.
Supports lack of proarrhythmic effects in animal models; leaves open confirmation in clinical populations.
The positive inotropic and chronotropic actions of enoximone were confirmed. At concentrations within the clinical range, enoximone prolonged the chronotropic and hypotensive action of isoproterenol in pithed rats. Very high doses of both enoximone and isoproterenol caused ventricular fibrillation in only one of six rats. In isolated rabbit atria, the maximum frequency at which pacing stimuli were followed 1:1 was increased by enoximone, and atrial flutter was consistently induced, then terminated by greatly suprathreshold stimulation. Enoximone significantly shortened action potential duration (APD), but did not exacerbate the APD-shortening induced by hypoxia. Since such hypoxia-induced shortening occurred in the presence of glucose 11 mmol/L and oxygen 20%, it was concluded that it was unlikely to have been caused by the opening of ATP-regulated potassium channels. These animal experiments suggest that enoximone, at concentrations encountered clinically in humans, does not have any electrophysiologic actions that would be likely to increase the probability of arrhythmias.
No takes yet. Share an insight, caveat, or question.
E. M. Vaughan Williams (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: